The role of SGLT2 inhibitors beyond glucose-lowering to cardio-renal protection

The role of SGLT2 inhibitors beyond glucose-lowering to cardio-renal protection

People with type 2 diabetes mellitus (T2DM) are at high risk of developing cardiovascular disease (CVD) and kidney disease. This enhanced cardio-renal risk persists despite improvements in care and treatments over the last 20 years. Intensive glucose control alone does not substantially reduce the r...

書目詳細資料
主要作者:	J. Karalliedde
格式:	Article
語言:	Russian
出版:	«FIRMA «SILICEA» LLC 2021-04-01
叢編:	Российский кардиологический журнал
主題:	cardiovascular disease hospitalization for heart failure end stage kidney disease
在線閱讀:	https://russjcardiol.elpub.ru/jour/article/view/4323

相似書籍

Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction
由: John S. Clemmer, et al.
出版: (2023-06-01)

Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i
由: Massimo Mapelli, et al.
出版: (2023-06-01)

Editorial: Recent advancement of the cardio-renal protective effects of SGLT2 inhibitors in people with and without diabetes
由: Satoru Kuriyama, et al.
出版: (2023-10-01)

Assessment of Relationship between Galectin-3 and Biochemical Parameters in Peritoneal Dialysis Patients with Left Ventricular Hypertrophy
由: Sultan Alouffi, et al.
出版: (2020-08-01)

Myocardial Cytoskeletal Adaptations in Advanced Kidney Disease
由: Arvin Halim, et al.
出版: (2022-03-01)

Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors?
由: José C. De La Flor, et al.
出版: (2023-07-01)

Risk prediction modeling for cardiorenal clinical outcomes in patients with non-diabetic CKD using US nationwide real-world data
由: Christoph Wanner, et al.
出版: (2025-01-01)

Exploring SGLT-2 Inhibitors: Benefits beyond the Glucose-Lowering Effect—What Is New in 2023?
由: Clipper F. Young, et al.
出版: (2023-09-01)

Incidence of end‐stage renal disease after heart transplantation and effect of its treatment on survival
由: Stefan Roest, et al.
出版: (2020-04-01)

Major cardiovascular events and associated factors among routine hemodialysis patients with end-stage renal disease at tertiary care hospital in Somalia
由: Mohamed Farah Yusuf Mohamud, et al.
出版: (2023-05-01)

Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care dataResearch in context
由: Brendon L. Neuen, et al.
出版: (2024-02-01)

SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
由: Carlo Garofalo, et al.
出版: (2019-06-01)

ISCHEMIC HEART DISEASE AND RENAL DYSFUNCTION
由: F. I. Belyalov
出版: (2017-07-01)

SGLT2 inhibitors: Beyond glycemic control
由: Irtiza Hasan, et al.
出版: (2024-03-01)

SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
由: Jonathan C. H. Chan, et al.
出版: (2023-02-01)

Management of Cardiovascular Diseases in Chronic Hemodialysis Patients
由: Zhen Zhang, et al.
出版: (2023-06-01)

Incident heart failure and the subsequent risk of progression to end stage kidney disease in individuals with type 2 diabetes
由: Sylvia Liu, et al.
出版: (2024-06-01)

Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome
由: Hiroki Akiyama, et al.
出版: (2023-01-01)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
由: Natalia G. Vallianou, et al.
出版: (2021-06-01)

Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
由: André J. Scheen
出版: (2024-01-01)

SGLT2i: beyond the glucose-lowering effect
由: Lihua Ni, et al.
出版: (2020-06-01)

Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review
由: Angelica Cersosimo, et al.
出版: (2024-10-01)

New insights into the cardio-renal benefits of SGLT2 inhibitors and the coordinated role of miR-30 family
由: Abdellatif El Khayari, et al.
出版: (2024-11-01)

Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?
由: Asmaa Elrakaybi, et al.
出版: (2022-10-01)

Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods
由: Hai‐Bin Chen, et al.
出版: (2023-04-01)

Predictors of cardiovascular disease in peritoneal dialysis patients: A Prospective longitudinal cohort study
由: I. Shifris, et al.
出版: (2022-11-01)

Pathophysiology of the cardio-renal syndromes types 1–5: An uptodate
由: L. Di Lullo, et al.
出版: (2017-03-01)

Impact of end stage renal disease on the clinical outcomes of diabetics admitted for heart failure: Analysis of national inpatient sample
由: Muhammad Usman Almani, et al.
出版: (2023-03-01)

Editorial: CaRe Me: improving the cardio-renal-metabolic care of patients through clinical and translational research
由: José Jesús Broseta, et al.
出版: (2024-07-01)

Incident heart failure and the subsequent risk of progression to end stage kidney disease in individuals with type 2 diabetes
由: Liu, Sylvia, et al.
出版: (2024)

Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Renal Function in Patient with Heart Failure
由: Teruhiko Imamura, et al.
出版: (2021-12-01)

Editorial: Clinical prospective of SGLT2 inhibitors in atherosclerosis
由: Annalisa Capuano, et al.
出版: (2022-11-01)

The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys
由: Eirini Lioudaki, et al.
出版: (2022-03-01)

The Role of Omentin-1 in Cardio-renal Syndrome
由: Nagham Q. Kazim, et al.
出版: (2016-03-01)

Oral Anticoagulant Initiation in Patients With Kidney Failure on Hemodialysis Newly Diagnosed With Atrial Fibrillation (2007-2020): An Observational Study of Trends and Disparities
由: Wolfgang C. Winkelmayer, et al.
出版: (2025-02-01)

The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective
由: Saverio Muscoli, et al.
出版: (2022-08-01)

Aging is associated with slower renal progression in patients with chronic kidney disease
由: Chia-Tse Yeh, et al.
出版: (2022-01-01)

Lactobacilli species diversity in gut microbiota of renal failure patients
由: Gholamreza Hanifi, et al.
出版: (2020-06-01)

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
由: Emily Brown, et al.
出版: (2021-01-01)

Nursing Home Status Adjustment for Standardized Mortality and Hospitalization in Dialysis Facility ReportsPlain-Language Summary
由: Shu Chen, et al.
出版: (2023-02-01)